ESR1 and breast carcinoma: The vast majority of ER + breast cancers are clearly also AR + (84 to 91%)[5,37,38] and patients with tumors that co-express AR with ER and PR have a longer DFS than those with tumors negative for all three receptors[37], probably reflecting a more well-differentiated state than that of receptor-negative tumors .